



# CABBACIS

Developing  
**Harm Reduction Products**  
for the World's 1 Billion Smokers

# Forward Looking Statements

This presentation has been prepared by Cabbacis Inc (the "Company") solely for informational purposes. The information included in this presentation has not been independently verified. No representations, warranties or undertakings, express or implied, are made by the Company or any of its affiliates, advisers or representatives as to, and no reliance should be placed upon, the accuracy, fairness, completeness or correctness of the information or opinions presented or contained in this presentation. By viewing or accessing the information contained in this presentation, you acknowledge and agree that none of the Company or any of its affiliates, advisers or representatives accept any responsibility whatsoever (in negligence or otherwise) for any loss howsoever arising from any information presented or contained in this presentation or otherwise arising in connection with the presentation. The information presented or contained in this presentation is subject to change without notice and its accuracy is not guaranteed. None of the Company or any of its affiliates, advisers or representatives make any undertaking to update any such information subsequent to the date hereof except as required by law. This presentation should not be construed as legal, tax, investment or other advice.

The Company has filed an offering statement on Form 1-A (Regulation A) with the Securities and Exchange Commission ("SEC"), File No. 024-12621, relating to the proposed public offering of its securities in the United States, which the SEC qualified on November 24, 2025. The proposed offering of the Company's securities to be made in the United States will be made solely on the basis of the offering statement. Any decision to purchase the Company's securities in the proposed offering should be made solely on the basis of the information contained in the offering circular. This presentation should be read together with the amended offering statement, which may be accessed through the following link:

[sec.gov/Archives/edgar/data/1987010/000121390025115315/ea0267460-253g2\\_cabbacis.htm](https://www.sec.gov/Archives/edgar/data/1987010/000121390025115315/ea0267460-253g2_cabbacis.htm)

This presentation contains statements that reflect the Company's intent, beliefs or current expectations about the future. These forward-looking statements can be recognized by the use of words such as 'expect,' 'may,' 'plan,' 'should,' 'anticipate,' 'will,' 'would' 'could,' 'assume,' 'potential,' 'believe,' 'predict,' 'estimate,' 'intend,' 'propose,' 'may,' 'target,' 'objective,' 'position,' any negatives of these terms, and other similar meanings and expressions that predict future events. These forward-looking statements are made only, and are based on, estimates and information available to the Company, as of the date of this presentation, and are not guarantees of future performance. All statements other than statements of historical fact in this presentation are forward-looking statements, including but not limited to, the Company's goals and growth strategies; the Company's expectations regarding demand for and market acceptance of the Company's brands and products; the Company's future business development, results of operations and financial condition; the Company's ability to maintain and improve the Company's infrastructure necessary to operate the Company's business; the Company's ability to use proceeds from its proposed offering in the manner contemplated by the Company; the Company's ability to comply with the continued listing standards of OTC Markets Group; the Company's ability to operate as a public company; the period of time for which its current liquidity will enable the Company to fund its operations; general economic and business conditions; the volatility of the Company's operating results and financial condition and the price of its ordinary shares; the Company's ability to attract and retain qualified senior management personnel and research and development staff; and assumptions underlying or related to any of the foregoing and other risks detailed in the Company's filings with the Securities and Exchange Commission (SEC). All of the Company's SEC filings, including the offering statement, are available on the SEC's website which may be accessed through the following link:

<https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001987010&owner=include&count=40>.

These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that its expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results. We describe the risks, uncertainties and assumptions that could affect the Company's business, including its financial conditions and results of operations, under "Risk Factors" section of the offering statement on Form 1-A (File No. 024-12621).

Statistical data in this presentation include projections based on a number of assumptions. Failure of the Company's industry to grow may have a material and adverse effect on its business and the market price of its securities. Furthermore, if any one or more of the assumptions underlying the market data are later found to be incorrect, actual results may differ from the projections based on these assumptions. You should not place undue reliance on these forward-looking statements.

This presentation does not constitute an offer to sell or an invitation to purchase or subscribe for any securities of the Company for sale in the United States or anywhere else. No part of this presentation shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Specifically, these materials do not constitute a "prospectus" within the meaning of the U.S. Securities Act of 1933, as amended, and the regulations enacted thereunder. This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to the risks and special considerations involved with an investment in the securities of the Company and is qualified in its entirety by reference to the detailed information in the offering statement relating to the proposed offering. Any decision to purchase the Company's securities in the proposed offering should be made solely on the basis of the information contained in the offering statement relating to the proposed offering.

All the third-party trademarks, names, and other information that appear in this presentation are used for information and comparison only and do not mean that we have been given authorization to use such information.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or the accuracy or adequacy of this presentation. Any representation to the contrary is a criminal offense.





# Presenting Today



**Joseph Pandolfino**

**Founder & CEO**



**CABBACIS**



**CABBACIS**

# Reg A Offering

**Cabbacis is raising up to \$7.5 Million**

## REG A Offering

- Open to accredited and non-accredited U.S. investors
- Open to anyone outside of the U.S. at or over the age of 18
- Fully compliant with U.S. securities laws
- Early-stage investing opportunity
- Investing in U.S. company

## Investment Terms

- Common Stock
- \$2.00 per share
- Up to 3.75 M shares being offered
- No warrants
- Minimum Investment: \$1,000

**Learn More and Invest at [www.invest.cabbacis.com](http://www.invest.cabbacis.com)**

**Invest  
Now**



# Corporate Overview

Cabbacis is a tobacco product manufacturer focused on commercializing risk-reduction products – led by the flagship iBLEND™ cigarettes and vaporizer pods.

- **Developing flagship iBLEND™ products (cigarettes & vaporizer pods containing both very-low-nicotine tobacco and hemp) to help smokers smoke less, reduce nicotine dependence & exposure, and increase quit attempts**
  - Hemp is not intoxicating (<0.3% THC) and is legal nationwide under the 2018 Farm Bill
  - Nicotine level in tobacco reduced by ~95%
- **Large Addressable Market:** Tobacco is an accelerating \$1 Trillion market globally, with about half of adult smokers seeking to quit each year
- **Significant Regulatory Tailwinds:** FDA plan to significantly reduce nicotine levels in all cigarettes in the U.S. creates compelling market advantage and forces tobacco industry to seek new alternatives
- **Broad Intellectual Property Moat:** 36 issued product patents (8 in the U.S.) covering cigarettes and vaporizer pods
- **Established Production Capacity:** Facilities and licenses in place with ~\$75M annual revenue capacity which is easily expandable
- **Proven Management Team:** Established history of value creation in the tobacco space



## OTCQB: CABI <sup>1</sup>

|                    |                   |
|--------------------|-------------------|
| Share Price        | \$2.00            |
| Market Cap         | \$15.9 M          |
| Shares Outstanding | 7.95 M            |
| Float              | 1.1 M             |
| Headquarters       | Niagara Falls, NY |

1. As of August 5, 2026



# Experienced Management Team

**Joseph Pandolfino, Founder and CEO.** Joe is the inventor on the company's patents and leads the strategic direction of Cabbacis. He is also the founder, and was the first CEO, of 22nd Century Group, Inc. (Nasdaq: XXII) and led the process of 22nd Century becoming publicly traded in 2011. Under his leadership, the company up-listed to the New York Stock Exchange in 2013 and achieved a market capitalization of \$373 million in 2014. Joe rang the Closing Bell at the New York Stock Exchange on October 16, 2014. He left 22nd Century as CEO later in 2014 and as a director in 2015. Joe's previous company funded the R&D project of reducing nicotine in tobacco by genetic engineering that resulted in the lowest-nicotine-content tobacco variety ever commercialized. A plant variety protection or PVP certificate (No. 200100039) was granted from the USDA for this tobacco variety, and the technology, variety rights, and related patent rights were spun out by Joe to a newly formed company, 22nd Century Limited. He has 35 years' experience in all aspects of the tobacco industry, including product development and marketing, and has more than 10 years' experience in both plant biotechnology and cannabis. He holds an MBA from the University at Buffalo.


**Michael R. Moynihan, PhD, R&D Director.** Mike has more than 30 years' experience in all aspects of plant biotechnology, ranging from molecular genetics to development of novel consumer products. He led R&D efforts at 22nd Century Group for 11 years, during which he played a major role in the development and production of Nicotine Research Cigarettes with different nicotine contents for the National Institute on Drug Abuse (NIDA). The Nicotine Research Cigarette series included cigarettes with nicotine concentrations ranging from higher than average to less than 5% of typical commercial cigarettes. Data from studies using these cigarettes, much of it funded by the National Institutes of Health and the Center for Tobacco Products of the Food and Drug Administration, provided the foundation for the authorization for sale of a very low nicotine cigarette brand as a Modified Risk Tobacco Product (MRTP) in the United States. Mike's other professional experience includes serving as Director of Biotechnology Development at Fundación Chile, Senior Project Director at InterLink Biotechnologies LLC, Principal Scientist, Cell Biology at EniChem Americas Inc., Visiting Research Fellow at the Institute for Molecular and Cellular Biology, Osaka University, Postdoctoral Associate in the Section of Plant Biology, Cornell University, and Postdoctoral Associate at the Center for Agricultural Molecular Biology, Rutgers University. Dr. Moynihan holds an ScB in Biology from Brown University and an MA and PhD in Biology from Harvard University.

**John C. Manley, Jr., CPA, Chief Financial Officer.** Entrepreneurial CPA, business coach, and strategist whose "highest and best" use is managing businesses. Jack has over 30 years' experience establishing, managing, restructuring, and selling privately held businesses. Extensive experience as a business leader in the health care, real estate, professional services, mortgage banking, distribution, and logistics industries. Founded U.S. Appraisal and serving as CEO, launched this regional real estate valuation services company into a national mortgage-industry leader. Led acquisition team in acquiring a large regional distribution company and completely redeveloped its infrastructure over a three-year period. Jack is committed to operational fundamentals and controls, with Big Four auditing experience at Deloitte. He holds a BS from Niagara University and is a Certified Public Accountant, licensed by the New York State Education Department.



# Market Opportunity


## Global Tobacco Market



### Market Highlights:

- \$1 Trillion Market
- Increasing demand for reduced-risk & cessation products
- Smoking Cessation & Nicotine De-Addiction Product Market:
  - \$34.0B in 2025 and expected to grow at a CAGR of 9.7% to \$53.9B by 2030 <sup>3</sup>
- Rising disposable incomes in developing regions

## U.S. Tobacco Market



### Market Highlights:

- Increasing demand for reduced-risk & cessation products
  - Innovations like e-cigarettes and heated tobacco products (e.g., VUSE<sup>®</sup> and IQOS<sup>®</sup>) support broader adoption of reduced-risk products
  - Market for products assisting in smoking less, reducing nicotine dependence, quitting and/or transitioning to less harmful products is expected to grow rapidly
- Almost half of adult cigarette smokers in the U.S. attempt to quit each year, but less than 10 percent are successful



# FDA Plan for Maximum Nicotine Level in Cigarettes

- January 15, 2025: The U.S. Food and Drug Administration issued a proposed rule<sup>1</sup> that, if finalized, **would limit the level of nicotine in cigarettes and certain other combusted tobacco products in the United States**
- This rule would cap nicotine at 0.7 milligrams per gram of tobacco: a **~95% reduction** from the average nicotine content found in popular cigarette brands today
- FDA's goal is to help smokers quit and prevent future generations from becoming addicted to nicotine
- **Other countries are expected to follow FDA policy**, which could drive an overnight shift in the dynamics of the global cigarette and tobacco products market

FDA NEWS RELEASE

## **FDA Proposes Significant Step Toward Reducing Nicotine to Minimally or Nonaddictive Level in Cigarettes and Certain Other Combusted Tobacco Products**

*Agency Encourages Public Input on Proposal That Aims to Prevent Millions of Premature Deaths*

For Immediate Release: January 15, 2025

*"Today's proposal envisions a future where it would be less likely for young people to use cigarettes and more individuals who currently smoke could quit or switch to less harmful products. This action, if finalized, could save many lives and dramatically reduce the burden of severe illness and disability, while also saving huge amounts of money. I hope we can all agree that significantly reducing the leading cause of preventable death and disease in the U.S. is an admirable goal we should all work toward."*

- FDA Commissioner





# Our Solution: iBLEND™ Botanical Blends

**iBLEND™ predominately contains tobacco  
and includes non-intoxicating hemp**

## Low Nicotine Tobacco

**Nicotine content  
reduced by ~95%**



Company contracts  
directly with farmers to grow



## Hemp

Very-Low THC &  
No-THC Cannabis

**THC content  
less than 0.3%**



Company contracts directly with  
farmers & sources from third parties

- Hemp is legal in the U.S. (on a national level) under the 2018 Farm Bill
- In focus groups, iBLEND's Taste was rated on par with usual brand cigarettes
  - iBLEND™ was rated higher by a very wide margin over very-low-nicotine cigarettes without hemp



**CABBACIS**



# iBLEND™ Product Focus Areas

## Very-Low-Nicotine Cigarettes



## Vaporizers Pods<sup>1</sup>



CABBACIS

1) Three exemplary vaporizers and pods, which are capable of utilizing blends of very-low-nicotine tobacco and hemp, are shown above: IQOS® is a registered trademark of Philip Morris Products S.A.; PAX® is a registered trademark of PAX Labs, Inc.; OMURA® is a registered trademark of Flat Planet LLC.

# Benefits Inherent to Flagship iBLEND™ Offering

## Very-Low-Nicotine Cigarettes

- Assists smokers to smoke less, reduce nicotine exposure, and increase quit attempts
- Assists smokers to transition to less harmful smoke-free products
- May assist marijuana smokers to smoke less marijuana



## Very-Low-Nicotine Vaporizer Pods

- iBLEND™ vapor is less harmful than smoking and not addictive like high-nicotine vapor
- Alternative to e-cigarettes or IQOS®
- May assist marijuana smokers/vapers use less marijuana



**Switching to less harmful products will become a necessity** for some if the FDA's product standard of capping nicotine content for all combustible cigarettes is implemented, **as the FDA has already announced.**





# Clinical Trial

Cabbacis contracted the Rose Research Center to carry out a pilot clinical trial on 16 smokers exclusively using four types of very-low-nicotine tobacco cigarettes made by Cabbacis during 3-hour *ad libitum* use sessions

Three iBLEND™ cigarette types contained very-low-nicotine tobacco and each type had a different level of hemp (5%, 10% and 20%), and the fourth cigarette type contained very-low-nicotine tobacco without any hemp

## RESULTS:

- Participants across all four cigarette types reported a significant reduction in craving for their usual brand of cigarettes which was sustained over the 3-hours of *ad libitum* use of the study cigarettes
- All four Cabbacis cigarette types were rated higher for satisfaction on the standardized mCEQ questionnaire than has been previously reported in the literature with other 95 percent reduced-nicotine cigarettes.
- An unexpected positive result of the study was that the use of the three iBLEND™ hemp-containing cigarettes (5%, 10% and 20%) resulted in lower exhaled carbon monoxide (CO) levels, as compared to CO levels measured after use of the 0-percent hemp cigarettes, with the reduction in the 20-percent hemp iBLEND™ cigarette being statistically significant at the 95 percent confidence level





# Cabbacis Expects to be **First to Market**

## Company IP Enables Cabbacis to be the Sole Provider of Very-Low-Nicotine Tobacco Products with Hemp in Countries with Patent Protection

**Relevant** to consumers as a better alternative due to product benefits



- iBLEND™ results in smoking or vaping less compared to conventional products
- Better sensory characteristics for smokers compared to other very-low-nicotine products

**Differentiated** as the only very-low-nicotine tobacco products which include hemp



- Upon implementation of FDA nicotine cap, iBLEND™ cigarettes will be greatly differentiated among all the other very-low-nicotine cigarettes
- **IP protects Cabbacis as the sole provider of very-low-nicotine cigarettes and pods with hemp**

**Not targeted** by Big Tobacco with lack of incentive to enter market



- Barrier from small-company patents including those of Cabbacis
- Entrance may accelerate timeline of FDA nicotine cap on cigarettes
- Niche market segment compared to conventional products



# Innovative SPECTRUM® Research Cigarettes

- Proprietary design created by Mr. Pandolfino and Dr. Moynihan
- **SPECTRUM® government research cigarettes** evaluated in more than 4 dozen independent clinical studies
  - 7 levels of nicotine from very low to conventional
- **Results demonstrate that subjects smoking SPECTRUM® cigarettes with the lowest nicotine levels:**
  - Smoked less, including fewer cigarettes per day
  - Reduced their nicotine dependence and exposure
  - Doubled their quit attempts
  - Increased their number of smoke-free days
- **Minimal or no evidence of compensatory smoking or nicotine withdrawal**



**Spectrum® study results are the basis for the FDA's proposed nicotine mandate**



# iBLEND™ U.S. Regulatory Path

## Clinical Trials

- Clinical trial compared very-low-nicotine cigarettes without hemp and 3 other styles with varying levels of hemp
- Dr. Jed Rose, coinventor of the nicotine patch, was the trial's Primary Investigator
  - Study was completed in **July 2025**
- Company has started a behavioral study and is planning a follow-up behavioral study and a consumer-perception study



## FDA Premarket Tobacco Product Applications (PMTAs) required for sale of iBLEND™ cigarettes and pods in the U.S.

- PMTA iBLEND™ cigarette filing expected by early 2027 with authorization in 2027/2028
- PMTA iBLEND™ vaporizer pod filing expected by 2028

## Modified Risk Tobacco Product (MRTP) Path

**Upon sufficient data, file an MRTP Application at FDA for iBLEND™ cigarettes & iBLEND™ vaporizer pods**

- NOT required to commercialize new products in U.S., but allows for product claims
- For authorization, MRTP application must demonstrate that the product will or is expected to benefit the health of the population as a whole
- The MRTP authorization for VLN® allowed the product claims (among others) "Helps You Smoke Less®" and "95% less nicotine" in advertising and on the label

**Company expects to commercialize internationally before the U.S. with potential out-licensing beforehand**



# Manufacturing Facility & Licenses

## 5,200 sq. ft. facility is strategically located within a large manufacturing complex

- Cabbacis has access to additional ~8,000 sq. ft. of hemp growing facilities and ~6,000 sq. ft. of GMP Certified processing/storage areas
- Growing operations are closely followed by the New York State Department of Agriculture to which all applicable documentation is submitted throughout the process
- Cigarette production equipment owned and kept on-site, capable of supporting at least \$75M of revenue capacity which is easily expandable

## Licenses Obtained


- TTB Permit (U.S. Treasury Dept) to Manufacture Tobacco Products
  - Allows for domestic production and exports
- New York State: Appointment of Distributor of Tobacco Products, License of Cigarette Agent, Hemp Grower License





# Worldwide Patent Protection

**36 Issued Patents  
Including 8 U.S. Patents  
plus various Pending Patent Applications**



- United States, Canada, Mexico, Brazil, Europe, United Kingdom, Switzerland, China, Russia, India, Japan, South Korea, Indonesia, Philippines, Australia, New Zealand and other jurisdictions
- Issued or pending patents in countries where about 2/3 of the world's one billion plus cigarette smokers and vapers reside



## **Cigarettes with blends of very-low-nicotine tobacco and hemp**

***Patent claims cover cigarettes comprising:***

- Any percentage of blends of tobacco and hemp which includes at least 2 mg hemp
- Nicotine content of cigarette of  $\leq 2$  mg
- THC content of hemp of  $\leq 1.25$  mg/g

## **Pods (for vaporizers) with blends of very-low or conventional nicotine tobacco and hemp**

***Patent claims cover pods comprising:***

- Any percentage of blends in pod of tobacco and hemp which includes at least 5 mg hemp
- Nicotine content of tobacco in pod  $\leq 3$  mg/g or at conventional levels, and
- THC content of hemp in pod is  $\leq 3$  mg/g



(10) Patent No.: US 12,527,346 B2  
(45) Date of Patent: Jan. 20, 2026

(52) U.S. Cl.  
CPC ..... *A24D 1/18* (2013.01); *A24B 15/12*  
(2013.01); *A24B 15/167* (2016.11); *A24B*  
*15/303* (2013.01); *A24D 1/002* (2013.01);  
*A24D 1/02* (2013.01); *A24F 40/50* (2020.01);  
*G09B 19/00* (2013.01)

(58) **Field of Classification Search**  
None  
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

|             |                       |
|-------------|-----------------------|
| (56)        | References Cited      |
|             | U.S. PATENT DOCUMENTS |
| 3,612,066 A | 10/1971 Jones et al   |
| 3,943,945 A | 3/1976 Rosen          |
| 4,037,609 A | 7/1977 Newton et al   |
|             | (Continued)           |

FOREIGN PATENT DOCUMENTS

|    |         |    |         |
|----|---------|----|---------|
| WO | 9428142 | A1 | 12/1994 |
| WO | 9856923 | A1 | 12/1998 |

(Continued)

## OTHER PUBLICATIONS

Todd, et al., "A functional genomics screen identifies diverse transcription factors that regulate alkaloid biosynthesis in *Nicotiana benthamiana*", *The Plant Journal*, vol. 62, 2010, pp. 589-600 (12 pages total).

(Continued)

Primary Examiner—Katherine A Will

*Primary Examiner*—Katherine A Will



# Growth Strategy

## Potential to Become a Major Player in Global Nicotine-Reduction Movement

### U.S. Market Pathway for iBLEND™

- **File 2 U.S. Premarket Tobacco Applications (PMTAs) at FDA**
  1. iBLEND™ cigarettes expected by early 2027
  2. iBLEND™ vaporizer pods expected by 2028 (could be sooner with partner/licensee)
    - FDA review process is 180 business days but is expected to be longer


### U.S. Market Pathway for Very-Low-Nicotine Cigarettes Without Hemp

- **FDA submission expected in late 2026 though an “Exemption from Substantial Equivalence” filing**
  - PMTA submission not expected to be required
  - Brand name TBD

### International Market Launch (Near-Term Revenue Focus)

- Production for select foreign markets
- Plan to initiate commercial rollout by early 2027
  - Enables early revenue generation and brand validation ahead of U.S. entry
- Prioritize 2–3 countries with lower regulatory barriers as test markets

**Strategic Global Expansion** - Actively exploring licensing and partnership opportunities during U.S. regulatory review phase and positioning Cabbacis to scale efficiently once U.S. regulatory approvals are secured



# Capital Raise and Select Financials

## Current Regulation A+ Capital Raise

- Targeting \$7.5M (3.75 M shares at \$2/share)
  - **For Operations for at least 2 years**, including G&A, remaining clinical trials, regulatory expenses, tobacco & hemp plantings, IP, machinery, and potential acquisitions
  - No warrants

## Clean Balance Sheet

- No Debt (other than accruals)

## Cap Table

- 7.95 M Common Shares issued & outstanding
  - Tightly held by insiders (~89% insider ownership)
- 0.6 M Series A Preferred Shares outstanding
- 0.4 M Options (\$2.00 strike price) outstanding
- Zero outstanding warrants


## Target Product-Level Gross Margins

- Management expects high 60% product-level gross margins for iBLEND™ at scale





# Use of Offering Proceeds



# Investment Highlights

- **First-to-Market Advantage:** Commercializing iBLEND™ very-low-nicotine cigarettes and pods with hemp, ahead of FDA nicotine cap
- **Breakthrough Product Design:** iBLEND™ uses ~95% less nicotine and <0.3% THC hemp – compliant, non-intoxicating, and legal under the 2018 Farm Bill
- **Massive Market Opportunity:** Targeting \$1T global tobacco market and \$34B+ cessation market
- **Regulatory Tailwinds:** FDA's nicotine-reduction proposal creates urgent need for compliant alternatives
- **Robust Patent Portfolio:** 36 granted patents (8 in U.S.) covering hemp-tobacco blends for cigarettes and vaporizers
- **Ready-to-Scale Infrastructure:** Licensed manufacturing facility with \$75M annual capacity already in place
- **Veteran Leadership:** Proven track record commercializing very-low-nicotine tobacco technologies



# Q&A

Learn More and Invest at [www.invest.cabbacis.com](http://www.invest.cabbacis.com)

Invest  
Now





# CABBACIS

OTCQB: [CABI](#)

## Investor Relations

MZ Group

Main: 949-259-4987

Email: [support@cabbacis.com](mailto:support@cabbacis.com)

[cabbacis.com](http://cabbacis.com)

